To study the effect of early lymphocyte recovery post-allogeneic hematopoietic stem cell transplantation (HSCT) on outcome in pediatric ALL, we reviewed 136 consecutive pediatric patients with ALL who received allogeneic HSCT between 1994 and 2005 at the Hospital for Sick Children, Toronto, Canada. Patients with an absolute lymphocyte count (ALC) o0.3 Â 10 9 per liter at day 21 (n ¼ 104) had more than five times risk of relapse compared to those with ALC 40.3 Â 10 9 per liter (n ¼ 32) (hazard ratio (HR) 5.3; P ¼ 0.002) and had inferior 3-year event-free survival, (EFS), 0.42 (95% confidence interval (CI) 0.32, 0.51) compared to 0.66 (95% CI 0.48, 0.82; P ¼ 0.02). Similarly, patients with an ALC o0.3 Â 10 9 per liter (n ¼ 48) at day 30 were more than twice as likely to relapse compared to those with an ALC 40.3 Â 10 9 per liter (n ¼ 88) (HR 2.2; P ¼ 0.01) and had an inferior 3-year EFS, 0.30 (95% CI 0.18, 0.45) compared to 0.57 (95% CI 0.46, 0.68; P ¼ 0.0001). Interestingly, increasing ALC at days 21 and 30 was not associated with increased incidence of acute or chronic GVHD or transplant-related mortality (TRM). Early lymphocyte recovery post-HSCT is associated with a significant GVL without increase in GVHD.
Introduction
Allogeneic hematopoietic stem cell transplantation (HSCT) is currently an established treatment for children with relapsed or high-risk ALL. 1, 2 Relapse is a major risk post-HSCT and an important cause of treatment failure with abysmal outcome. 3 Therapeutic options are limited for those who relapse post-allogeneic HSCT as their response to further chemotherapy is very poor since a significant number of these patients develop refractory disease, and second transplantation in lymphoid malignancies has limited efficacy. 3, 4 An important therapeutic mechanism of allogeneic HSCT is the immune-mediated destruction of recipient leukemic cells by donor lymphocytes, the GVL. The repopulating lymphocytes post-allogeneic HSCT play a vital role, not only in preventing serious infections in the early post-transplantation period, but by destroying residual tumor cells by GVL effect and has significant impact on the transplant outcome in terms of rate of relapse. [5] [6] [7] Previous studies have shown that delayed lymphocyte recovery post-allogeneic HSCT is associated with increased risk of relapse in acute myelogenous and lymphoid leukemia in adults. [8] [9] [10] [11] [12] The clinical induction of GVL effect offers a new approach for patients who relapse post-HSCT. 13 This has most commonly been as donor lymphocyte infusion (DLI), and several reports have demonstrated long-term survival with this approach. [14] [15] [16] Other options are rapid withdrawal of immunosuppressive medications and use of cytokines such as interferon-a and IL-2 to enhance GVL effect. 17, 18 Such measures can induce or enhance GVL effect and at the same time may potentially cause severe GVHD. 14, 16, 19 These measures are normally taken after diagnosing relapse or impending relapse from indications such as decreasing donor chimerism and increasing host cells. 20 However, there is good evidence that such immune-targeted measures work better when there is minimal disease and not impending or frank relapse. Therefore, identifying patients at high risk of relapse early may help to intervene with such immune measures prior to frank relapse. Hence the need for prognostic variables that can prospectively identify patients at high risk of relapse early in the post-transplantation period and thereby help select appropriate patients for further therapy such as immune therapy. Our primary objective was to examine if delayed lymphocyte recovery measured by the absolute lymphocyte count (ALC) at two time points post-HSCT, days 21 and 30, correlates with relapse in childhood ALL. Our secondary objective was to examine the effect of these early lymphocytes on survival and GVHD occurrence.
Materials and methods

Patients and donors
A total of 136 consecutive pediatric patients with ALL who received allogeneic HSCT between 1994 and 2005 at the Hospital for Sick Children, Toronto, Canada were reviewed. All patients were in complete morphological remission prior to HSCT. A total of 132 children received unmanipulated bone marrow grafts, two patients received GCSF peripherally mobilized unmanipulated stem cells due to donor-recipient size discrepancy and two patients received unrelated cord progenitor stem cells. Patients with mixed lineage/biphenotypic acute leukemia and patients with Down's syndrome were excluded. Since length of remission prior to HSCT in relapsed ALL has prognostic significance, we measured the length of first remission in CR2 and CR3 patients. Patient characteristics are described in Table 1 . The leukocyte counts, both total and differential for days 21 and 30 post-HSCT, were collected from medical records and electronic database. Two groups were identified based on the ALC of o0.3 Â 10 9 per liter and 40.3 Â 10 9 per liter for the analysis of the impact of days þ 21 and þ 30 ALC on risk of relapse and survival. The cutoff of 0.3 Â 10 9 per liter was chosen as a mid value based on previous adult published literature. [8] [9] [10] [11] [12] 21 When days 21 or 30 fell on a weekend or there was no differential count available, the ALC 1-2 days prior and 1-2 days post days 21 or 30 were taken into account. Patients with a low white cell count that did not allow differential counts or those with nonengraftment at days 21 or 30 were classified to be in the o0.3 Â 10 9 per liter groups.
Conditioning regimens
Pretransplant conditioning regimens included single dose of VP16 (60 mg/kg infused over 4 h) and fractionated TBI (fTBI; 1200 cGy) in six fractions over 3 days (VP16/fTBI) in 50 patients (1994) (1995) (1996) (1997) (1998) and cyclophosphamide 50 mg/kg infused over 1 h daily for 4 days followed by the same dose of fractionated TBI (CY/fTBI) in 83 patients (1999) (2000) (2001) (2002) (2003) (2004) (2005) . Two patients received cyclophosphamide 50 mg/kg infused over 30 min daily for 4 days along with ATG 30 mg/kg infused over 6 h daily for 3 days, and one patient received VP16 (60 mg/kg) infused over 4 h along with same dose of ATG.
Supportive care
All patients were nursed in protective isolation in single rooms with high efficiency particulate air filters. All patients received fluconazole for fungal prophylaxis, ganciclovir for CMV prophylaxis if the donor or recipient serostatus for CMV is positive. Pneumocystis pneumonia prophylaxis continued for at least 6 months post-HSCT. Pneumococcal prophylaxis with penicillin continued for at least 1-year post-HSCT or until vaccinated with pneumococcal vaccine. Fever during the neutropenic phase was treated with broad-spectrum antibiotics and amphotericin or caspofungen as necessary and modified subsequently according to the results of blood or tissue cultures. Blood products were transfused to maintain hemoglobin concentration 470 mg/l and platelet counts of 20 000 mm
À3
. CMV-negative patients were transfused with CMV-negative blood products and all blood products were irradiated.
GVHD prophylaxis
This consisted of MTX and cyclosporine A (CSA), except for two patients in whom tacrolimus was used along with MTX and one patient in whom MTX/mycophenolate was used. For the two patients who received cord progenitor stem cells, GVHD prophylaxis was with CSA and methylprednisolone. The CSA was administered intravenously at a dose of 3 mg/kg per day in two divided doses starting from the day before stem cell infusion until patients were able to tolerate oral cyclosporine. The dose of cyclosporine was titrated to maintain plasma levels between 150 and 200 ng/l when unrelated donors were utilized as stem cell source and 100 and 150 ng/l for related donors transplantations. MTX dosage was 10 mg/m 2 intravenously on days þ 3, þ 6, þ 11 and þ 18.
Assessment of engraftment, GVHD, relapse and treatment-related mortality
The day of stem cell infusion was defined as day 0. The marrows were infused unmanipulated except as required for donor-recipient ABO blood group incompatibility. The day of engraftment was defined as the first of 3 consecutive days in which the peripheral absolute neutrophil count is 40.5 Â 10 9 per liter. Acute GVHD was graded as 0-1 V according to the criteria of Glucksberg et al. 22 Chronic GVHD was defined as none, limited or extensive according to standard criteria. 23 Treatment-related mortality was defined as any death in remission. Patients who died from complications of a second transplantation or donor leukocyte infusion therapy given for recurrent disease were defined to have died from disease relapse. Relapse was described by either morphological evidence of disease in the peripheral blood, marrow, extramedullary sites or by the recurrence and sustained presence of pretransplant chromosomal abnormalities based on cytogenetic analysis of bone marrow cells.
End points
The primary end points of the study were disease relapse or death (event) post-HSCT as a measure for the event-free survival (EFS) and to assess the role of ALC in predicting the risk of relapse. The secondary objective end point was acute and chronic GVHD occurrence related to ALC at days 21 and 30.
Statistical analysis
The SAS software was used to perform statistical analyses. Time to event and the 3-year probability of EFS for different endpoints was determined using Kaplan-Meier curves. The log rank test was used to assess the differences between survival curves for the two different groups of patients. The association between pairs of categorical variables was evaluated using Fisher's exact test. The cumulative incidence of relapse and transplant-related mortality (TRM) at 3-years was estimated taking into account competing risks of other events. Cox proportional hazard survival model was used to examine multiple prognostic variables impact on survival.
Results
Patient demographics and transplant characteristics
Patient demographics and transplant characteristics are reported in Table 1 . A total of 136 consecutive children with ALL received allogeneic HSCT during the study period. Expectedly patients in CR2 constitute more than half of the total number. Indications for HSCT in CR2 varied over time. However, time and site of relapse were 9 per liter at days 21 and 30 post-HSCT. Patient demographics included gender, age at original diagnosis and HSCT, ALL phenotype, remission status, length of remission prior to HSCT in relapsed ALL, conditioning regimens, indications of HSCT in CR1 and stem cell source. There were no statistical differences in patients' characteristics between the two groups at days 21 and 30 taking into account a P-value of 0.1.
Lymphocyte recovery, myeloid engraftment, GVHD and transplant-related mortality As expected, there were more patients in the 40.3 Â 10 9 per liter group at day 30 compared to day 21 (88 versus 32), Table 1 . Three patients died in the early post-transplant period and were not evaluable for engraftment, ALC and GVHD. Table 2 demonstrates that, although lymphocyte recovery was different between the groups, neutrophil engraftment did not differ. Furthermore, incidence of acute, chronic GVHD and TRM did not differ among the groups. A total of 3-year estimates for TRM for all patients was 17% with 24 patients died from TRM or nonrelapse mortality. Causes of death included; infection and severe sepsis in 11 patients, pulmonary complications in 9 patients, veno-occlusive disease with multiorgan failure in two patients, cardiac failure in one patient and acute encephalopathy in one patient. There was a trend for more TRM for patients in the o0.3 Â 10 9 per liter group at day 30 (25 versus 14%, P-value 0.07).
Relapse and EFS
There was a statistically significant increase in relapse rate for patients with an ALC o0. conditioning regimens (VP16/TBI versus CY/TBI) and donor source (related versus unrelated). The ALC count at days 21 and 30 continued to be the only variable with a significant impact on outcome in this multivariate analysis as shown in Table 3 .
Discussion
In this large single center study of pediatric ALL patients receiving allogeneic HSCT, we found that delayed lymphocyte recovery as reflected by an ALC of o0.3 Â 10 9 per liter at days 21 and 30 post-HSCT is associated with a significant increase in relapse. Days 21 and 30 post-HSCT are still early for full engraftment studies by DNA chimerisms, but since patients had engrafted or were engrafting at that time, we hypothesize that these lymphocytes are donor and not host lymphocytes. We acknowledge the limitations of not knowing the exact phenotype of these early lymphocytes. However, our data suggest that these early donor lymphocytes play a vital role in eradicating residual leukemia without causing an increase in GVHD. These unique lymphocyte features are suggestive of natural killer (NK) cells and there is good evidence that NK cells are among the early subsets of lymphocytes to recover after allogeneic HSCT. Multiple factors may affect outcome in children receiving allogeneic HSCT for ALL. Remission status, length of remission in relapsed disease, cytogenetics, donor source, supportive care, stem cell and radiation technology and the degree of HLA typing, particularly when utilizing multiple transplantation centers. Nonetheless, our study is a single center study where uniform HLA and radiation technology, supportive care and transplantation indications were used. Patient characteristics including the important prognostic risk factors such as ALL biology and phenotype; cytogenetics for CR1 patients; number of CR1, 2 and 3 patients; length of remission for CR2 and 3 patients and donor source were all comparable among the ALC o0.3 Â 10 9 per liter and the ALC 40.3 Â 10 9 per liter groups at days 21 and 30 post-HSCT. TBI-based conditioning regimens were used with combination of VP16 (1994-1998) and cyclophosphamide (1999) (2000) (2001) (2002) (2003) (2004) (2005) . The change from VP16/TBI to CY/TBI in 1998 was made for administrative reasons and to follow what was felt to be a more commonly used conditioning regimen in North American institutions. Comparable outcome of these two different regimens has been validated in our institution. 26 Furthermore, in the Cox proportional hazard model, the two most commonly used conditioning regimens, VP16/ TBI and CY/TBI, had the same impact on survival outcome. The results of our study demonstrate the prognostic importance of the rate of lymphocyte recovery post-allogeneic HSCT independent of age, disease status at transplantation, conditioning regimens and donor source. Our findings are consistent with what has been reported previously. [8] [9] [10] [11] [12] 21 However, to the best of our knowledge, our study is the largest pediatric study.
The GVL effect plays a vital role for the success of allogeneic HSCT in leukemia along with the diseasereducing mechanisms of the high-dose chemoradiotherapy. GVL effect first became evident when Weiden et al. 27 more than 25 years ago reported the decreased rate of leukemia relapse associated with acute or chronic GVHD. This has been proven later in larger studies. 13, 28 However, GVL effect is not entirely dependent on GVHD. 29 Evidence for GVL includes higher relapse rate after T cell-depleted transplants, 30 and remission induction after donor leukocyte infusion in patients with leukemia relapsing post transplantation. 6, 14, 15 The effector mechanism of GVL and GVHD are complex and incompletely understood. CD4 þ , CD8 þ T lymphocytes and NK cells are considered major players. 29, 31 The early post-transplantation period is the most critical as the disease burden is lowest at this time and chances of eliminating it completely through immune mechanism are highest. During the early post-transplantation period the majority of the peripheral blood mononuclear cells are NK cells that are capable of mediating cytotoxicity without prior sensitization and may be responsible for most of early antileukemic activity of allograft. 32, 33 This is supported by the increased risk of relapse associated with delayed recovery of NK cells. 31 This correlation of increased relapse associated with delayed lymphocyte recovery post-HSCT observed in this study has practical significance as it identifies the group of patients with increased risk of relapse who may be suitable candidates for targeted early intervention. Potential therapeutic options could be administration of interferon, ILs, use of DLI or rapid curtailment of immunosuppression therapy. Interferon-a and IL-2 can upregulate NK cells and could enhance the cytotoxicity against various cell lines and has been shown to decrease the relapse rate after T celldepleted allogeneic HSCT. 17, 18, 34 Prophylactic use of DLI and rapid taper of immunosuppression have been used with success but are associated with increased incidence of GVHD, if tapered too rapidly. 15, 16 In recent years, there has been growing evidence that NK cells play a vital role in the early post-HSCT period not only to enhance GVL or graft versus tumor effect but also to reduce GVHD. [35] [36] [37] We cannot explain why donor lymphocytes vary in their recovery in the leukemic host post-infusion. It is very likely to be multifactorial and possibly there are donor and recipient factors. Moreover, it is intriguing to continue to have relapses/events in the ALC o0.3 Â 10 9 per liter group even years after HSCT, while there were no events in the ALC 40.3 Â 10 9 per liter group after 3 years. This suggests that GVL effect happens very early post-HSCT and relapse time varies and could happen after many years depending on disease kinetics, and the speed of the disease to produce enough leukemia burdens to cause frank relapse.
HSCT outcomes for pediatric ALL have been relatively stable in the last 20 years and more chemotherapy or radiotherapy does not offer better outcome due to more toxicity. However, as our knowledge and therapeutic options expand, the ability to limit GVHD while preserving antimicrobial and augmenting GVL becomes a realistic prospect and further studies of immune biology, lymphocyte cooperation and the role of regulatory T and NK cells will lead to better strategies to exploit adoptive transfer of lymphocytes for therapeutic benefit.
In conclusion, delayed lymphocyte recovery on days 21 and 30 after HSCT for pediatric ALL is a powerful predictor of relapse post-HSCT and helps to identify patients at a significant risk for relapse early in the post-transplantation period to potentially allow targeted intervention by immunotherapy such as withdrawal of immunosuppressive medications or enhancing GVL effect to prevent relapse and improve survival. Characteristics of these early lymphocytes are suggestive for NK cells. However, we feel this warrants further studies.
